Inhaled Frespaciguat Fails to Improve PH-COPD Outcomes
The Phase 2a INSIGNIA trial found the treatment did not significantly improve 6-minute walk distances.
Updated on Oct. 21, 2026 in Asthma
Live Poll
Do you believe experimental lung therapies should be prioritized even if early trials show limited benefits?
Inhaled frespaciguat did not meet its primary endpoint in the Phase 2a INSIGNIA PH-COPD trial, failing to show a statistically significant improvement in 6-minute walk distance compared to a placebo. The study evaluated the drug in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.
Why it matters
Researchers are now working to identify more appropriate clinical endpoints for future trials involving this patient population. The results highlight the ongoing difficulty in finding effective therapies for pulmonary hypertension linked to COPD.
The trial involved 128 randomized patients who were assessed after a 24-week intervention of 380 µg of frespaciguat. Baseline metrics showed a mean pulmonary vascular resistance of 6.2 Wood units.
The players
Medical University of Graz
This is an Austrian public medical university that serves as a center for research and clinical trials.
The details
Participants in the trial received the treatment or placebo once daily via a dry-powder inhaler. While the primary endpoint was not met, clinical worsening events were mainly attributed to COPD exacerbations, and adverse events were reported less frequently with frespaciguat than with the placebo group.
Timeline
The results were presented at the CHEST 2026 Annual Meeting between October 18-21, 2026.
The final assessment for the 6-minute walk distance occurred at week 24.
The Big Picture
This study updates data previously established by the INSIGNIA PH-COPD clinical trial program.
Patients currently managing pulmonary hypertension associated with COPD will not see a change in treatment availability based on these results. Doctors will continue to rely on existing standards of care as researchers search for new viable therapies.
The takeaway
This study underscores the complexity of treating pulmonary hypertension in patients with compromised lung function. Future trials may require refined endpoints to better measure therapeutic success for these patients.
Further reading
For more information on respiratory disease research, visit Asthma.
More information
View the trial study information for complete data.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you believe experimental lung therapies should be prioritized even if early trials show limited benefits?
